BRAF and neoplasm: This is not only the case for immune checkpoint inhibitors (ICIs), which directly derepress anti-tumor T cell immunity, but also for targeted BRAF and MEK inhibitors, the efficacy of which has been at least partly attributed to immune engagement23–28.